125 related articles for article (PubMed ID: 8120867)
21. Design and synthesis of potent, selective, and orally active fluorine-containing renin inhibitors.
Doherty AM; Sircar I; Kornberg BE; Quin J; Winters RT; Kaltenbronn JS; Taylor MD; Batley BL; Rapundalo SR; Ryan MJ
J Med Chem; 1992 Jan; 35(1):2-14. PubMed ID: 1732531
[TBL] [Abstract][Full Text] [Related]
22. Synthesis and structure-activity relationships of human renin inhibitors designed from angiotensinogen transition state.
Iizuka K; Kamijo T; Harada H; Akahane K; Kubota T; Etoh Y; Shimaoka I; Tsubaki A; Murakami M; Yamaguchi T
Chem Pharm Bull (Tokyo); 1990 Sep; 38(9):2487-93. PubMed ID: 2285979
[TBL] [Abstract][Full Text] [Related]
23. Novel small renin inhibitors containing 4,5- or 3,5-dihydroxy-2-substituted-6-phenylhexanamide replacements at the P2-P3 sites.
Jung GL; Anderson PC; Bailey M; Baillet M; Bantle GW; Berthiaume S; Lavallée P; Llinas-Brunet M; Thavonekham B; Thibeault D; Simoneau B
Bioorg Med Chem; 1998 Dec; 6(12):2317-36. PubMed ID: 9925293
[TBL] [Abstract][Full Text] [Related]
24. Novel renin inhibitors containing a non-peptide aminoalkanoyl moiety at P1-P1' position.
Winiecka I; Marszałek D; Goldnik A; Jaworski P; Mazurek AP
Pharmazie; 2014 Apr; 69(4):263-70. PubMed ID: 24791589
[TBL] [Abstract][Full Text] [Related]
25. Highly potent and specific inhibitors of human renin.
Sham HL; Stein H; Rempel CA; Cohen J; Plattner JJ
FEBS Lett; 1987 Aug; 220(2):299-301. PubMed ID: 3111889
[TBL] [Abstract][Full Text] [Related]
26. Statine-containing dipeptide and tripeptide inhibitors of human renin.
Kokubu T; Hiwada K; Nagae A; Murakami E; Morisawa Y; Yabe Y; Koike H; Iijima Y
Hypertension; 1986 Jun; 8(6 Pt 2):II1-5. PubMed ID: 3087874
[TBL] [Abstract][Full Text] [Related]
27. Discovery of non-peptidic P2-P3 butanediamide renin inhibitors with high oral efficacy.
Simoneau B; Lavallée P; Anderson PC; Bailey M; Bantle G; Berthiaume S; Chabot C; Fazal G; Halmos T; Ogilvie WW; Poupart MA; Thavonekham B; Xin Z; Thibeault D; Bolger G; Panzenbeck M; Winquist R; Jung GL
Bioorg Med Chem; 1999 Mar; 7(3):489-508. PubMed ID: 10220035
[TBL] [Abstract][Full Text] [Related]
28. Design of rat renin inhibitory peptides.
Hui KY; Holtzman EJ; Quinones MA; Hollenberg NK; Haber E
J Med Chem; 1988 Sep; 31(9):1679-86. PubMed ID: 3045320
[TBL] [Abstract][Full Text] [Related]
29. New renin inhibitors containing pseudodipeptidic units in P3-P2 and P1-P1' positions.
Paruszewski R; Jaworski P; Bodnar M; Dudkiewicz-Wilczyńska J; Roman I
Chem Pharm Bull (Tokyo); 2005 Oct; 53(10):1305-9. PubMed ID: 16204988
[TBL] [Abstract][Full Text] [Related]
30. Renin inhibitors containing conformationally restricted P1-P1' dipeptide mimetics.
Williams PD; Perlow DS; Payne LS; Holloway MK; Siegl PK; Schorn TW; Lynch RJ; Doyle JJ; Strouse JF; Vlasuk GP
J Med Chem; 1991 Mar; 34(3):887-900. PubMed ID: 2002469
[TBL] [Abstract][Full Text] [Related]
31. Acute hypotensive responses to peptide inhibitors of renin in conscious monkeys: an effect on blood pressure independent of plasma renin inhibition.
Schaffer LW; Schorn TW; Winquist RJ; Strouse JF; Payne L; Chakravarty PK; de Laszlo SE; tenBroeke J; Veber DF; Greenlee WJ
J Hypertens; 1990 Mar; 8(3):251-9. PubMed ID: 2159506
[TBL] [Abstract][Full Text] [Related]
32. Peptide analogues of angiotensinogen. Effect of peptide chain length on renin inhibition.
Plattner JJ; Greer J; Fung AK; Stein H; Kleinert HD; Sham HL; Smital JR; Perun TJ
Biochem Biophys Res Commun; 1986 Sep; 139(3):982-90. PubMed ID: 3533075
[TBL] [Abstract][Full Text] [Related]
33. Novel 2,7-dialkyl-substituted 5(S)-amino-4(S)-hydroxy-8-phenyl-octanecarboxamide transition state peptidomimetics are potent and orally active inhibitors of human renin.
Göschke R; Stutz S; Rasetti V; Cohen NC; Rahuel J; Rigollier P; Baum HP; Forgiarini P; Schnell CR; Wagner T; Gruetter MG; Fuhrer W; Schilling W; Cumin F; Wood JM; Maibaum J
J Med Chem; 2007 Oct; 50(20):4818-31. PubMed ID: 17824679
[TBL] [Abstract][Full Text] [Related]
34. Design of renin inhibitors containing conformationally restricted mimetics of the P1-P1' and P1 through P2' sites.
Williams PD; Payne LS; Perlow DS; Holloway MK; Siegl PK; Schorn TW; Lynch RJ; Doyle JJ; Strouse JF; Vlasuk GP
Adv Exp Med Biol; 1991; 306():325-34. PubMed ID: 1812722
[No Abstract] [Full Text] [Related]
35. Renin inhibitors containing a pyridyl amino diol derived C-terminus.
Heitsch H; Henning R; Kleemann HW; Linz W; Nickel WU; Ruppert D; Urbach H; Wagner A
J Med Chem; 1993 Sep; 36(19):2788-800. PubMed ID: 8410992
[TBL] [Abstract][Full Text] [Related]
36. Synthesis, biological evaluation and docking studies of octane-carboxamide based renin inhibitors with extended segments toward S3' site of renin.
Wu Y; Shi C; Sun X; Wu X; Sun H
Bioorg Med Chem; 2011 Jul; 19(14):4238-49. PubMed ID: 21708467
[TBL] [Abstract][Full Text] [Related]
37. New inhibitors of renin that contain novel phosphostatine Leu-Val replacements.
Dellaria JF; Maki RG; Stein HH; Cohen J; Whittern D; Marsh K; Hoffman DJ; Plattner JJ; Perun TJ
J Med Chem; 1990 Feb; 33(2):534-42. PubMed ID: 2105396
[TBL] [Abstract][Full Text] [Related]
38. Synthesis and optimization of novel (3S,5R)-5-(2,2-dimethyl-5-oxo-4-phenylpiperazin-1-yl)piperidine-3-carboxamides as orally active renin inhibitors.
Mori Y; Ogawa Y; Mochizuki A; Nakamura Y; Fujimoto T; Sugita C; Miyazaki S; Tamaki K; Nagayama T; Nagai Y; Inoue S; Chiba K; Nishi T
Bioorg Med Chem; 2013 Sep; 21(18):5907-22. PubMed ID: 23886807
[TBL] [Abstract][Full Text] [Related]
39. A novel nonpeptidic, orally active renin inhibitor.
Morishima H; Koike Y; Nakano M; Atsuumi S; Tanaka S; Funabashi H; Hashimoto J; Sawasaki Y; Mino N; Nakano M
Biochem Biophys Res Commun; 1989 Mar; 159(3):999-1005. PubMed ID: 2495004
[TBL] [Abstract][Full Text] [Related]
40. Design of potent substrate-analogue inhibitors of canine renin.
Hui KY; Siragy HM; Haber E
Int J Pept Protein Res; 1992 Aug; 40(2):152-60. PubMed ID: 1446972
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
